



DIGEST OF SB 150 (Updated March 14, 2007 5:44 pm - DI 77)

Citations Affected: IC 12-15; noncode.

Synopsis: Mental health quality advisory committee. Extends the expiration date for the mental health quality advisory committee from July 1, 2007, to July 1, 2009.

Effective: Upon passage.

Lawson C, Simpson

(HOUSE SPONSOR — BROWN C)

January 8, 2007, read first time and referred to Committee on Health and Provider Services.
February 22, 2007, reported favorably — Do Pass.
February 26, 2007, read second time, ordered engrossed. Engrossed.
February 27, 2007, read third time, passed. Yeas 48, nays 0.

HOUSE ACTION
March 6, 2007, read first time and referred to Committee on Public Health.
March 15, 2007, reported — Do Pass.





First Regular Session 115th General Assembly (2007)

PRINTING CODE. Amendments: Whenever an existing statute (or a section of the Indiana Constitution) is being amended, the text of the existing provision will appear in this style type, additions will appear in this style type, and deletions will appear in this style type.

Additions: Whenever a new statutory provision is being enacted (or a new constitutional provision adopted), the text of the new provision will appear in **this style type**. Also, the word **NEW** will appear in that style type in the introductory clause of each SECTION that adds a new provision to the Indiana Code or the Indiana Constitution.

Conflict reconciliation: Text in a statute in *this style type* or *this style type* reconciles conflicts between statutes enacted by the 2006 Regular Session of the General Assembly.

ENGROSSED SENATE BILL No. 150

A BILL FOR AN ACT to amend the Indiana Code concerning human services.

Be it enacted by the General Assembly of the State of Indiana:

SECTION 1. IC 12-15-35.5-7, AS AMENDED BY P.L.101-2005,
SECTION 7, IS AMENDED TO READ AS FOLLOWS [EFFECTIVE
UPON PASSAGE]: Sec. 7. (a) Subject to subsections (b) and (c), the
office may place limits on quantities dispensed or the frequency of
refills for any covered drug for the purpose of:

- (1) preventing fraud, abuse, or waste;
- (2) preventing overutilization, inappropriate utilization, or inappropriate prescription practices that are contrary to:
 - (A) clinical quality and patient safety; and
 - (B) accepted clinical practice for the diagnosis and treatment of mental illness; or
- (3) implementing a disease management program.
- (b) Before implementing a limit described in subsection (a), the office shall:
 - (1) consider quality of care and the best interests of Medicaid recipients;
- 17 (2) seek the advice of the drug utilization review board,

8

9

10

11 12

13 14

15

16

ES 150—LS 6667/DI 14+









1	established by IC 12-15-35-19, at a public meeting of the board;
2	and
3	(3) publish a provider bulletin that complies with the
4	requirements of IC 12-15-13-6.
5	(c) Subject to subsection (d), the board may establish and the office
6	may implement a restriction on a drug described in section 3(b) of this
7	chapter if:
8	(1) the board determines that data provided by the office indicates
9	that a situation described in IC 12-15-35-28(a)(8)(A) through
10	IC 12-15-35-28(a)(8)(K) requires an intervention to:
11	(A) prevent fraud, abuse, or waste;
12	(B) prevent overutilization, inappropriate utilization, or
13	inappropriate prescription practices that are contrary to:
14	(i) clinical quality and patient safety; and
15	(ii) accepted clinical practice for the diagnosis and treatment
16	of mental illness; or
17	(C) implement a disease management program; and
18	(2) the board approves and the office implements an educational
19	intervention program for providers to address the situation.
20	(d) A restriction established under subsection (c) for any drug
21	described in section 3(b) of this chapter:
22	(1) must comply with the procedures described in
23	IC 12-15-35-35;
24	(2) may include requiring a recipient to be assigned to one (1)
25	practitioner and one (1) pharmacy provider for purposes of
26	receiving mental health medications;
27	(3) may not lessen the quality of care; and
28	(4) must be in the best interest of Medicaid recipients.
29	(e) Implementation of a restriction established under subsection (c)
30	must provide for the dispensing of a temporary supply of the drug for
31	a prescription not to exceed seven (7) business days, if additional time
32	is required to review the request for override of the restriction. This
33	subsection does not apply if the federal Food and Drug Administration
34	has issued a boxed warning under 21 CFR 201.57(e) that applies to the
35	drug and is applicable to the patient.
36	(f) Before implementing a restriction established under subsection
37	(c), the office shall:
38	(1) seek the advice of the mental health quality advisory
39	committee until June 30, 2007; June 30, 2009; and
40	(2) publish a provider bulletin that complies with the
41	requirements of IC 12-15-13-6.
42	(g) Subsections (c) through (f):



1	(1) apply only to drugs described in section 3(b) of this chapter;
2	and
3	(2) do not apply to a restriction on a drug described in section
4	3(b) of this chapter that was approved by the board and
5	implemented by the office before April 1, 2003.
6	SECTION 2. P.L.101-2005, SECTION 8, IS AMENDED TO READ
7	AS FOLLOWS [EFFECTIVE UPON PASSAGE]: SECTION 8. (a) As
8	used in this SECTION, "committee" refers to the mental health quality
9	advisory committee established in subsection (c).
10	(b) As used in this SECTION, "office" refers to the office of
11	Medicaid policy and planning established by IC 12-8-6-1.
12	(c) The mental health quality advisory committee is established. The
13	committee consists of the following members:
14	(1) The director of the office or the director's designee, who shall
15	serve as chairperson of the committee.
16	(2) The director of the division of mental health and addiction or
17	the director's designee.
18	(3) A representative of a statewide mental health advocacy
19	organization.
20	(4) A representative of a statewide mental health provider
21	organization.
22	(5) A representative from a managed care organization that
23	participates in the state's Medicaid program.
24	(6) A member with expertise in psychiatric research representing
25	an academic institution.
26	(7) A pharmacist licensed under IC 25-26.
27	The governor shall make the appointments under subdivisions (3)
28	through (7) and fill any vacancy on the committee.
29	(d) The office shall staff the committee. The expenses of the
30	committee shall be paid by the office.
31	(e) Each member of the committee who is not a state employee is
32	entitled to the minimum salary per diem provided by IC 4-10-11-2.1(b).
33	The member is also entitled to reimbursement for traveling expenses
34	as provided under IC 4-13-1-4 and other expenses actually incurred in
35	connection with the member's duties as provided in the state policies
36	and procedures established by the Indiana department of administration
37	and approved by the budget agency.
38	(f) Each member of the committee who is a state employee is
39	entitled to reimbursement for traveling expenses as provided under
40	IC 4-13-1-4 and other expenses actually incurred in connection with
41	the member's duties as provided in the state policies and procedures

established by the Indiana department of administration and approved



42

1	by the budget agency.
2	(g) The affirmative votes of a majority of the voting members
3	appointed to the committee are required by the committee to take
4	action on any measure, including a final report.
5	(h) The committee shall advise the office and make
6	recommendations concerning the implementation of IC 12-15-35.5-7(c)
7	and consider the following:
8	(1) Peer reviewed medical literature.
9	(2) Observational studies.
10	(3) Health economic studies.
11	(4) Input from physicians and patients.
12	(5) Any other information determined by the committee to be
13	appropriate.
14	(i) The office shall report recommendations made by the committee
15	to the drug utilization review board established by IC 12-15-35-19.
16	(j) The office shall report the following information to the select
17	joint commission on Medicaid oversight established by IC 2-5-26-3:
18	(1) The committee's advice and recommendations made under this
19	SECTION.
20	(2) The number of instances that occur under the restriction
21	described in IC 12-15-35.5-7(c) and the outcome of each
22	occurrence.
23	(3) The transition of the aged, blind, and disabled population to
24	the risk based managed care program. This information shall also
25	be reported to the health finance commission established by
26	IC 2-5-23-3.
27	(4) Any decision by the office to change the health care delivery
28	system in which Medicaid is provided to recipients.
29	(k) This SECTION expires June 30, 2007. June 30, 2009.
30	SECTION 3. An emergency is declared for this act.



COMMITTEE REPORT

Madam President: The Senate Committee on Health and Provider Services, to which was referred Senate Bill No. 150, has had the same under consideration and begs leave to report the same back to the Senate with the recommendation that said bill DO PASS.

(Reference is made to Senate Bill 150 as introduced.)

MILLER, Chairperson

Committee Vote: Yeas 9, Nays 0.

C

COMMITTEE REPORT

Mr. Speaker: Your Committee on Public Health, to which was referred Senate Bill 150, has had the same under consideration and begs leave to report the same back to the House with the recommendation that said bill do pass.

BROWN C, Chair

Committee Vote: yeas 11, nays 0.



y

